Enbrel
Q2 2026 sales fell 4% to $580 million.
The numbers
Enbrel product sales$580 millionQ2 2026 · down 4% year over year · source ↗
What it is
Long-established biologic for rheumatoid arthritis and other inflammatory diseases. It is one of Amgen's oldest products and still a large seller.
Why it matters to the stock. Enbrel's slow decline is the steadiest part of Amgen's base business, so its trend is a read on pricing and competition in inflammatory disease.
News
Federal judge blocks Colorado's price cap on Amgen's Enbrel
A federal judge in Denver granted Amgen a preliminary injunction on July 1, 2026, blocking Colorado's Prescription Drug Affordability Review Board from capping the price of Enbrel while Amgen's lawsuit continues.
Legal